Variant · Expression
CRLF2 Overexpression
CI-VAR-00003193Explore in graph →CIViC 2739
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 30658992
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Childhood B-cell Acute Lymphoblastic Leukemia1unmapped disease | ||||||||
| CRLF2 Overexpression | (prognostic) | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID7364In adolescent/young adult (AYA) patients with B-ALL on CALGB 10403 study, CRLF2 overexpression was strongly associated with worse event free survival, disease free survival and overall survival. PMID 30658992 · Stock et al., 2019 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.